Authors of Genome Medicine Article Form Genetic Testing Company

by McDonnell Boehnen Hulbert & Berghoff LLP
Contact

Genome LibertyIn a paper published in March in the journal Genome Medicine, Dr. Jeffrey Rosenfeld of the University of Medicine & Dentistry of New Jersey and Dr. Christopher Mason of Cornell University contended that due to the non-specificity of sequence uniqueness across the genome and the broad scope of claims to nucleotide sequences, the Supreme Court and Congress should limit the patenting of existing nucleotide sequences ("Pervasive sequence patents cover the entire human genome," Genome Medicine 5:27 (2013)).  Their paper was discussed in this space shortly after publication (see "Genome Medicine Article Calls for Limits on Patenting of Existing Nucleotide Sequences" and "Revisiting Genome Medicine Article on 'Pervasive Sequence Patents' That 'Cover the Entire Human Genome'"), and was followed by a response from Dr. Mason (see "Dr. Chris Mason Responds to Blog Posts on Genome Medicine Article"), and then our discussion of the paper and Dr. Mason's response to our coverage concluded with two further posts (see "A Primer on Claim Construction -- Comments on Dr. Mason's Response" and "A Response to Dr. Mason's "Rebuttal" to Criticisms of His Genomics Medicine Article").  Last week, the co-authors of the paper announced that they had started a company, Genome Liberty, Inc., to determine the medications a person should take and the medications a person should avoid based upon that person's DNA.

In an e-mail distributed last week, Dr. Rosenfeld noted that the co-authors "are extremely proud that there are no longer patents on human genes and that researchers can sequence any gene without the risk of litigation."  With respect to the type of analyses that their company will perform, Dr. Rosenfeld provided two examples:  first, assaying for individuals who convert codeine to morphine in their livers too quickly, leading to an overdose of morphine (citing Kelly et al., 2012, "More Codeine Fatalities After Tonsillectomy in North American Children" Pediatrics 129(5): e1343-47), and second, testing for a condition known as Factor V Leiden where people who are given estrogen, either as birth control or as hormone replacement, can have severe blood clots.  In a follow-up e-mail distributed earlier today, Dr. Rosenfeld indicated that "[f]or a large percentage of medications, there are DNA markers indicating whether [such medications] should be used or avoided, but doctors do not routinely perform these tests."

In a statement released by the co-authors, they note that their company "will democratize the human genome and give people direct access to their own genetic information -- which can have an immediate impact on their health and well being," adding that the Supreme Court's decision in AMP v. Myriad Genetics "opened an era of genomic liberty, allowing people to look at the DNA for all of their genes -- which had been hidden behind patent walls for companies that had a monopoly on such testing."  The release states that the company will "begin offering immediate, personalized genetic testing to the public that can be directly ordered by patients," while suggesting that "the results should used in concert with your doctor."  The company's founders explain that:

Genome Liberty, with the Supreme Court's blessing, ushers in a new paradigm of personalized medicine, which complements the traditional health care model.  Previously, individuals had to rely on their doctors to understand their health and to make proper medical decisions for them.  Recently, people are becoming more involved in their own health care, in a phenomenon called "participatory medicine."  Various organizations, including patientslikeme.com and the Society for Participatory Medicine, have been leading the charge in this field to overcome inherent weaknesses in our medical system.  Many people have found that drugs do not work for them, and they have formed patient groups to attempt to help each other.  And, as scientists and doctors have found the molecular basis for disease and drug response, it has become increasingly clear that a "one-size-fits-all" framework for medicine is not in the best interest of each patient.

According to the release, Genome Liberty will be examining genetic markers associated with drug response for "hundreds of frequently prescribed drugs," including codeine, Plavix, Nexium, Prilosec, Zocor, Dilantin, Coumadin, Haloperidol, Abilify, and Celexa, and that the test will cost $99.

In an effort to secure funding for their new company, the co-authors have initiated a crowd-funding campaign on the website RocketHub.  As of August 12, 40 funders had committed $8,285 towards a goal of $100,000 to be raised by September 5.  The company's RocketHub page includes the following video discussing the AMP v. Myriad Genetics decision and the company's plans:

Please click link for video.

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP
Contact
more
less

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
Feedback? Tell us what you think of the new jdsupra.com!